Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...
GlobalData on MSN6d
MSD commences Phase III trial of DLBCL treatmentMSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...
The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...
AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast ...
In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback